# US 2019/0054110 A1 · Modulators of ccr9 for treating tumor resistance to immune responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054110 A1
- Document ID: US20190054110A1
- Status: Published application
- Kind: A1
- Application number: 16/077,698
- Filed: 2017-02-16
- Published: 2019-02-21
- Earliest claimed: 2016-02-16
- Applicants: Deutsches Krebsforschungszentrum Stiftung Des öFfentlichen Rechts
- Inventors: Nisit KHANDELWAL; Philipp BECKHOVE; Michael BOUTROS; Marco BREINIG; Tillmann MICHELS
- Web page: https://patentgrep.com/patent/US20190054110A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/505: {involving T-cells}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention pertains to novel modulators of tumor resistance against T-cell mediated cytotoxic immune responses. The invention provides antagonists of tumor immune escape mechanisms and methods and other aspects related thereto, and therefore provides novel approaches for treating or aiding a treatment of various cancerous diseases and/or the diagnosis thereof. The invention specifically discloses C—C chemokine receptor type 9 (CCR9) as a checkpoint molecule in tumor resistance against cytotoxic T-cells. Provided is the inhibition of CCR9 expression, CCR9 signalling and/or CCR9-T-Cell interaction and inhibitors or antagonists thereof. In particular aspects, the invention provides combination therapeutics and/or therapies involving such inhibitors or antagonists. The invention furthermore provides screening methods for novel cancer therapeutics modulating CCR9 action, diagnostic approaches to detect cancer resistance to cytotoxic T-cells as well as pharmaceutical compositions and diagnostic kits for performing, for use with or related to these methods.

## Claims

### Claim 1

A combination comprising (a) and (b); or (a) and (c); or (a), (b) and (c); wherein
(a) Is an inhibitor or antagonist of CCR9,
(b) Is an inhibitor or antagonist of PI3K-Akt signaling and/or an inhibitor or antagonist of p70S6 kinase signaling, and
(c) Is an activator or agonist of ERK1/2 signaling and/or an activator or agonist of JNK signaling.

### Claim 2 (depends on 1)

The combination according to claim 1, wherein the combination is a pharmaceutical composition, or is a plurality of pharmaceutical compositions, comprising (a) and (b), or (a) and (c), or (a) and (b) and (c).

### Claim 3 (depends on 1, 2)

The combination according to claim 1 or 2, comprising (a) and (b), wherein (b) is, an inhibitor or antagonist of PI3K-Akt signaling.

### Claim 4 (depends on 1, 2)

The combination according to claim 1 or 2, comprising (a) and (b), wherein (b) is, an inhibitor or antagonist of p70S6 kinases signaling, preferably an inhibitor of S6K.

### Claim 5 (depends on 1, 2)

The combination according to claim 1 or 2, comprising (a) and (b), wherein (b) is an mTOR/PI3K dual inhibitor or a dual S6K and Akt inhibitor.

### Claim 6 (depends on 1, 2)

The combination according to claim 1 or 2, comprising (a) and (b), wherein (b) comprises MK-2206 (CAS NO: 1032350-13-2).

### Claim 7 (depends on 1, 2)

The combination according to claim 1 or 2, comprising (a) and (b), wherein (b) comprises MSC-2363318A (CAS NO: 1379545-95-5).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The combination according to any one of claims 1 to 7, wherein (a) is an antibody that binds to CCR9 and inhibits CCR9 expression and/or CCR9-T-cell interaction and/or CCR9 cell signaling.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The combination according to any one of claims 1 to 7, wherein (a) is a nucleic acid, preferably an siRNA, that inhibits CCR9 expression and/or CCR9-T-cell interaction and/or CCR9 cell signaling.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for treating a tumor disease of a patient, wherein the tumor disease is characterized by a resistance of a tumor cell to a T cell mediated immune response of the patient, the method comprising a step of administering to the patient a therapeutically effective amount of the combination according to any one of claims 1 to 9, preferably by administering to the patient a therapeutically effective amount of the components (a) and (b), or (a) and (c), or (a) and (b) and (c) of such combination.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the inhibitor or antagonist of CCR9 is selected from an inhibitor or antagonist of CCR9 expression, an inhibitor or antagonist of CCR9 signaling, or an inhibitor or antagonist of CCR9-T-cell interaction.

### Claim 12 (depends on 10, 11)

The method according to claim 10 or 11, wherein said tumor cell is characterized by a detectable cell surface expression of CCR9.

### Claim 13 (depends on 11, 12)

The method according to claim 11 or 12, wherein said inhibitor of CCR9-T-cell interaction is an inhibitor of CCR9 mediated STAT1 impairment in T-cells.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The combination according to any one of claims 1 to 9, or the method according to any one of claims 10 to 13, wherein said inhibitor or antagonist of CCR9, said inhibitor or antagonist of PI3K-Akt signaling and/or said inhibitor or antagonist of p70S6 kinase signaling, and/or said activator or agonist of ERK1/2 signaling and/or said activator or agonist of JNK signaling, is a compound selected from a polypeptide, peptide, glycoprotein, a peptidomimetic, an antibody or antibody-like molecule; a nucleic acid such as a DNA or RNA, for example an antisense DNA or RNA, a ribozyme, an RNA or DNA aptamer, siRNA, shRNA and the like, including variants or derivatives thereof such as a peptide nucleic acid (PNA); a targeted gene editing construct, such as a CRISPR/Cas9 construct, a carbohydrate such as a polysaccharide or oligosaccharide and the like, including variants or derivatives thereof; a lipid such as a fatty acid and the like, including variants or derivatives thereof; or a small organic molecules including but not limited to small molecule ligands, small cell-permeable molecules, and peptidomimetic compounds.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The method according to any one of claims 10 to 14, wherein said tumor cell, tumor or tumor disease is characterized by a resistance against T-cell mediated cytotoxicity.

### Claim 16 (depends on 10, 11, 12, 13, 14, 15)

The method according to any one of claims 10 to 15, wherein said tumor cell, tumor or tumor disease is selected from a liquid or solid tumor, and preferably is breast cancer, ovarian cancer, cancer of the colon and generally the gastro-intestinal tract, lung cancer, e.g., small-cell lung cancer and non-small-cell lung cancer, renal cancer, bladder cancer, prostate cancer, skin cancer like melanoma, head and neck cancer or a tumor disease of the central nervous system, e.g., cervix cancer and, in particular, a brain tumor, more especially astrocytoma, e.g., glioma, or blood cancer such as leukemia (or a tumor cell derived therefrom).

### Claim 17 (depends on 10, 11, 12, 13, 14, 15)

The method according to any one of claims 10 to 15, wherein said tumor or tumor disease is multiple myeloma or said tumor cell is a multiple myeloma cell.

### Claim 18 (depends on 10, 11, 12, 13, 14, 15, 16, 17)

The method according to any one of claims 10 to 17, wherein said inhibitor or antagonist of CCR9 is an inhibitor or antagonist of CCR9-T-cell interaction, and said CCR9-T-cell interaction is a CCR9 mediated binding of said tumor cell to said T-cell, for example by intermolecular interaction between cell surface expressed CCR9 on said tumor cell and at least one T-cell component expressed on the cellular surface of said T-cell.

### Claim 19 (depends on 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method according to any one of claims 10 to 18, wherein components (a) and (b), or (a) and (c), or (a) and (b) and (c), of said combination, are combined by sequential or concomitant administration to a subject suffering from the tumor disease during said treatment, preferably wherein (a) and (b), or (a) and (c), or (a) and (b) and (c) are concomitantly administered during said treatment.

### Claim 20

A method for identifying a compound suitable for the treatment of a tumor disease, the method comprising the steps of
(a) Providing a first cell expressing a CCR9 protein on the cellular surface,
(b) Providing a candidate compound,
(c) Optionally, providing a second cell which is a cytotoxic T-lymphocyte (CTL), preferably that is capable of immunologically recognizing said first cell, and
(d) Bringing into contact the first cell and the candidate compound, and optionally the second cell, and
(e) Determining subsequent to step (d), either or both of:
i. CCR9 expression in said first cell, wherein a reduced CCR9 expression in said first cell contacted with the candidate compound compared to said first cell not contacted with said candidate compound indicates that the candidate compound is a compound suitable for the treatment of a tumor disease; and/or
ii. cytotoxicity of said CTL against said first cell, wherein an enhanced cytotoxicity of said CTL against said first cell contacted with the candidate compound compared to the cytotoxicity of said CTL against said first cell not contacted with the candidate compound indicates that the candidate compound is a compound suitable for the treatment of a tumor disease.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said first cell is a cell resistant to cytotoxicity mediated by T-lymphocytes, preferably a tumor derived cell.

### Claim 22 (depends on 20, 21)

The method according to claim 20 or 21, wherein, said tumor disease or tumor derived cell is selected from a liquid or solid tumor, and preferably is breast cancer, ovarian cancer, cancer of the colon and generally the gastro-intestinal tract, lung cancer, e.g., small-cell lung cancer and non-small-cell lung cancer, renal cancer, bladder cancer, prostate cancer, skin cancer like melanoma, head and neck cancer or a tumor disease of the central nervous system, e.g., cervix cancer and, in particular, a brain tumor, more especially astrocytoma, e.g., glioma, or blood cancer such as leukemia (or a tumor cell derived therefrom).

### Claim 23 (depends on 20, 21)

The method according to claim 20 or 21, wherein said tumor disease is multiple myeloma or said tumor derived cell is a cell derived from a multiple myeloma.

### Claim 24 (depends on 20, 21, 22, 23)

The method according to any one of claims 20 to 23, wherein said tumor disease is resistant against T cell mediated immune responses

### Claim 25 (depends on 20, 21, 22, 23, 24)

The method according to any one of claims 20 to 24, wherein said candidate compound is selected from a polypeptide, peptide, glycoprotein, a peptidomimetic, an antibody or antibody-like molecule; a nucleic acid such as a DNA or RNA, for example an antisense DNA or RNA, a ribozyme, an RNA or DNA aptamer, siRNA, shRNA and the like, including variants or derivatives thereof such as a peptide nucleic acid (PNA); a targeted gene editing construct, such as a CRISPR/Cas9 construct, a carbohydrate such as a polysaccharide or oligosaccharide and the like, including variants or derivatives thereof; a lipid such as a fatty acid and the like, including variants or derivatives thereof; or a small organic molecules including but not limited to small molecule ligands, small cell-permeable molecules, and peptidomimetic compounds.

### Claim 26

A method for reducing resistance of a tumor cell to an immune response, the method comprising a step of contacting the tumor cell with a modulator of tumor resistance selected from an inhibitor or antagonist of CCR9.

### Claim 27 (depends on 26)

The method according to claim 26, comprising a step of contacting the tumor cell with an inhibitor of CCR9 expression, an inhibitor of CCR9 signaling or an inhibitor of CCR9-T-cell interaction.

### Claim 28 (depends on 27)

The method according to claim 27, wherein said tumor cell is characterized by a detectable cell surface expression of CCR9 before contacting the tumor cell with an inhibitor of CCR9 expression or an inhibitor of CCR9-T-cell interaction or an inhibitor of CCR9 signaling.

### Claim 29 (depends on 27, 28)

The method according to claim 27 or 28, wherein said inhibitor of CCR9-T-cell interaction is an inhibitor of CCR9 mediated STAT1 impairment in T-cells.

### Claim 30

A method for treating a tumor disease in a patient, wherein said tumor disease is characterized by resistance of said tumor against immune responses, the method comprising a step of inhibiting in said patient CCR9 expression in said tumor, and/or inhibiting in said patient CCR9 mediated interaction of at least one tumor cell of said tumor with at least one T-cell of said patient, and/or inhibiting in said patient CCR9 signaling in said tumor.

### Claim 31

A method for aiding a patient's immune response against a tumor disease comprising a step of inhibiting in said patient CCR9 expression in said tumor, and/or inhibiting in said patient CCR9 mediated interaction of at least one tumor cell of said tumor with at least one T-cell of said patient, and/or inhibiting in said patient CCR9 signaling in said tumor.

### Claim 32 (depends on 30, 31)

The method according to claim 30 or 31, comprising a step of administering to said patient a therapeutically effective amount of an inhibitor of CCR9 expression and/or an inhibitor of CCR9-T-cell interaction and/or an inhibitor of CCR9 signaling.

### Claim 33 (depends on 27, 28, 29, 32)

The method according to any one of claims 27 to 29 and 32, wherein said inhibitor of CCR9 expression or said inhibitor of CCR9-T-cell interaction or said inhibitor of CCR9 signaling is a compound selected from a polypeptide, peptide, glycoprotein, a peptidomimetic, an antibody or antibody-like molecule; a nucleic acid such as a DNA or RNA, for example an antisense DNA or RNA, a ribozyme, an RNA or DNA aptamer, siRNA, shRNA and the like, including variants or derivatives thereof such as a peptide nucleic acid (PNA); a targeted gene editing construct, such as a CRISPR/Cas9 construct, a carbohydrate such as a polysaccharide or oligosaccharide and the like, including variants or derivatives thereof; a lipid such as a fatty acid and the like, including variants or derivatives thereof; or a small organic molecules including but not limited to small molecule ligands, small cell-permeable molecules, and peptidomimetic compounds.

### Claim 34 (depends on 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any one of claims 26 to 33, wherein said tumor cell, tumor or tumor disease is selected from a liquid or solid tumor, and preferably is breast cancer, ovarian cancer, cancer of the colon and generally the gastro-intestinal tract, lung cancer, e.g., small-cell lung cancer and non-small-cell lung cancer, renal cancer, bladder cancer, prostate cancer, skin cancer like melanoma, head and neck cancer or a tumor disease of the central nervous system, e.g., cervix cancer and, in particular, a brain tumor, more especially astrocytoma, e.g., glioma, or blood cancer such as leukemia (or, in each case, a tumor cell thereof).

### Claim 35 (depends on 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any one of claims 26 to 33, wherein said tumor or tumor disease is multiple myeloma or said tumor cell is a multiple myeloma cell.

### Claim 36 (depends on 27, 28, 29, 32, 33)

The method according to any one of claims 27 to 29, 32 and 33, wherein said CCR9-T-cell interaction is a CCR9 mediated binding of said tumor cell to said T-cell, for example by intermolecular interaction between cell surface expressed CCR9 on said tumor cell and at least one T-cell component expressed on the cellular surface of said T-cell.

### Claim 37

A method for diagnosing in a patient a resistance of a tumor disease against T cell mediated immune responses, the method comprising a step of determining expression of CCR9 in a tumor cell from the tumor of the patient, wherein a detectable expression of CCR9 in the tumor cell compared to a negative control is indicative for a resistance of the tumor disease against T cell mediated immune responses.

### Claim 38 (depends on 37)

The method according to claim 37, comprising a preceding step of obtaining a tumor cell from the patient.

### Claim 39 (depends on 37, 38)

The method according to claim 37 or 38, wherein said expression of CCR9 is a cell surface expression of CCR9 on the tumor cell.

### Claim 40 (depends on 37, 38, 39)

The method according to any one of claims 37 to 39, wherein, said tumor disease is selected from a liquid or solid tumor, and preferably is breast cancer, ovarian cancer, cancer of the colon and generally the gastro-intestinal tract, lung cancer, e.g., small-cell lung cancer and non-small-cell lung cancer, renal cancer, bladder cancer, prostate cancer, skin cancer like melanoma, head and neck cancer or a tumor disease of the central nervous system, e.g., cervix cancer and, in particular, a brain tumor, more especially astrocytoma, e.g., glioma, or blood cancer such as leukemia.

### Claim 41 (depends on 37, 38, 39)

The method according to any one of claims 37 to 39, wherein said tumor disease is multiple myeloma.
